Labiana lifts EBITDA 10.2% and posts 41.26 million euros in first-half revenue
Labiana Health, a Spanish pharmaceutical group listed on BME Growth, reported revenue of 41.26 million euros in the first half of 2026, up 5.2%, with adjusted EBITDA of 8.20 million (+10.2%) and adjusted EBIT of 6.19 million (+14.2%). Animal Health grew 9.6% and accounted for 50.3% of sales. Net income was 0.93 million, after 3.5 million in extraordinary financial expenses from cancelling the previous financing with Miralta/Blantyre.
In 35 seconds
- Revenue of 41.26 million euros, up 5.2%, and adjusted EBITDA of 8.20 million (+10.2%)
- Animal Health grew 9.6% to 20.77 million and represented 50.3% of consolidated revenue
- Net income fell to 0.93 million due to 3.5 million in extraordinary financial expenses tied to cancelling the previous financing
IASummary generated by artificial intelligence from a story by 3tres3.com. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.